Hepatocellular carcinoma (HCC) is the most common primary neoplasm of the liver and a significant cause of mortality in patients with cirrhosis. Aim of this review is to summarize the new methods of diagnosis and therapeutic options.
Background
HCC has become the third most common malignancy worldwide with very poor prognosis, rendering it the fourth highest cause of cancer related deaths 1, 2 . The distribution of liver cancer varies by region and more than 80% of cases and deaths occur in developing countries 3 . In Africa, liver cancer has been ranked as the fourth common cancer, and most of liver cancers are HCC 4 .
Epidemiology
HCC represents 85%-90% of primary liver cancers accounting for 3.5% and 7.5% of all cancers among women and men respectively, and accounts for half a million deaths per year. In Middle Eastern countries, liver cancer is a major concern among men, especially in certain countries such as Egypt and Saudi Arabia, and to a lesser extent in other countries of this region. Recent reports demonstrate that the incidence of HCC has increased sharply in the last 5-10 years, with an especially high incidence in Egypt 5 . DCP is an abnormal prothrombin protein that is found in the serum of patients with HCC and in patients with vitamin K-deficiency or on warfarin therapy 10 .
Risk factors

Glypican-3 (GPC3)
It is an oncofetal protein expressed in fetal liver and HCC. A clinical trial using a GPC3 peptide vaccine in patients with advanced HCC has been carried out, denoting that it serves not only as a tumor marker but also as a therapeutic target 11 .
Squamous cell carcinoma antigen (SCCA)
\SCCA is physiologically expressed in the skin and other squamous epithelial cells 12 . It has been reported to be overexpressed in HCC tissue and in serum from patients with HCC 13 .
3.
Golgi protein 73 (GP73, also known as Golph2)
It is a protein expressed by biliary epithelial cells in normal liver. It is upregulated in patients with acute hepatitis, cirrhosis and HCC 14 .
Hepatocyte growth factor (HGF)
HGF has been used as a prognostic marker in HCC. Serum HGF levels greater than or equal to 1.0 ng/mL have been associated with poor survival in HCC patients 15 .
• Imaging diagnosis Imaging studies for diagnosis of HCC can fall into one of two main categories: routine non-invasive studies such as US, CT, and MRI, and more specialized invasive techniques including CT during hepatic arteriography, iodised oil-CT, and CT arterial portography in addition to the conventional hepatic angiography 16 .
Abdominal ultrasonography (US)
Abdominal US allows the recognition of tumours as small as 1 cm in size 16 . US offers many signs that raise the suspicion of malignant transformation, including the presence of intrahepatic venous thrombosis, a mass protruding from the hepatic surface or dilated intrahepatic bile duct, even in the absence of a definite liver mass 17 .
Multislice-helical (spiral) CT
Abdominal multiphase perfusion CT is the technique of choice for diagnosis of HCC with an excellent performance in the early detection and staging of hepatic focal lesions
17
. The gold standard imaging modality for evaluating the response after locoregional intervention of HCC is Spiral CT 18 .
Magnetic resonance imaging (MRI)
The advantage of MRI over CT is obtaining images of the liver of highresolution without using ionizing radiation or nephrotoxic contrast agents. MRI has an equivalent diagnostic accuracy as helical CT in the early detection and diagnosis of HCC 19 . Therapeutic options HCC therapies are categorized as curative and palliative, which depend upon the tumor features, hepatic reserve, and presence or not of extrahepatic metastasis or vascular invasion. Manifold current treatment choices include: Surgical resection, liver transplantation, radiofrequency ablation (RFA), microwave ablation, percutaneous ethanol injection (PEI) or acetic acid ablation, transcatheter arterial chemoembolization (TACE), radioembolization, cryoablation, radiation therapy (RT), stereotactic radiotherapy, systemic chemotherapy, molecularly targeted therapies like sorafenib 20 , and viscum fraxini 21 Summary and conclusion HCC is one of the commonest cancers worldwide. It is a major health problem and its incidence is increasing. More than 600,000 people die from it each year. The presence of cirrhosis is the major risk factor and this is largely due to chronic HCV and HBV infection.
Worldwide research on the disease needs to be intensified in both the medical and pharmaceutical fields, especially with a focus on providing help to areas where resources are limited. 
